5959 Cornerstone Court West
About ImpediMed Inc.ImpediMed develops bioimpedance devices with a focus on medical applications in the fluid status area. Primary to this is the L-Dex U400 which measures extracellular fluid differences in the limbs for unilateral lymphedema.
The company is pioneering the use of next generation bioimpedance technology in BIS (Bioimpedance Spectroscopy).
Founder: Mel Bridges
CEO: Richard Carreon
Please click here for ImpediMed job opportunities.
PRODUCTS: All Products
38 articles with ImpediMed Inc.
ImpediMed Limited, a global medical technology company using bioimpedance spectroscopy to generate powerful data to improve patient health, announced the release of the next generation software for the SOZO® Digital Health Platform.
New Data Show ImpediMed's Lymphedema Prevention Program Reduces Incidence of Chronic Lymphedema in Breast Cancer Patients and Survivors
ImpediMed Limited, a global medical technology company using bioimpedance spectroscopy to generate powerful data to improve patient health, announced the publication of a new study demonstrating that the company's Lymphedema Prevention Program reduces the incidence of chronic breast cancer-related lymphedema in breast cancer patients and survivors.
ImpediMed and The US Oncology Network Sign Agreement for Major Roll-Out of SOZO® Technology as Part of Lymphedema Prevention Program
ImpediMed Limited, a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), today announced a national purchasing a
Recommendations align with protocols outlined in ImpediMed's Lymphedema Prevention Program [13-February-2020] CARLSBAD, Calif. , and BRISBANE, Australia , Feb. 13, 2020 /PRNewswire/ -- ImpediMed Limited (ASX.IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscop
ImpediMed Limited, a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy, recently announced the issuance of a further 510 clearance for SOZO® by the U.S. Food and Drug Administration.
The claims around PCM are to aid clinicians who are using Subjective Global Assessment (SGA) tools to assess patients at risk of PCM.
ImpediMed Limited announces the kickoff of the company's new, comprehensive Lymphedema Prevention Program with the goal of ending cancer-related lymphedema.
Professor Sheila Ridner, PhD, RN, FAAN, the Martha Rivers Ingram Professor of Nursing at Vanderbilt University School of Nursing, Principal Investigator, PREVENT trial.
Trial results on lymphoedema treatment using an Australian deviceshows strong improvement in patient outcomes
ImpediMed will become Business Associate-compliant and launch third-generation software for its award-winning SOZO Digital Health Platform.
ImpediMed Announces PREVENT Trial Accepted for Publication and Presentation at the 2019 Annual Meeting of the American Society of Breast Surgeons
Largest prospective, multi-center, randomized trial undertaken in the prevention of breast cancer-related lymphedema
Early Surveillance with L-Dex® Reduces Incidence, Severity & Cost of Breast Cancer-Related Lymphedema, ImpediMed Reports Publication in American Cancer Society Journal
ImpediMed Limited today announced the publication of a landmark study from the prominent research institute Macquarie University.
ImpediMed Highlights Publication of Recommendations in New England Journal of Medicine: Supports Use of Bioimpedence and L-Dex Measurement for Lymphedema Assessment
International authority on lymphedema, Stanley G. Rockson, M.D., calls for use of Bioimpedance Spectroscopy as protocol in surveillance and assessment of cancer survivors
ImpediMed’s SOZO® Digital Health Platform Voted Among Top Five Finalists for Southern California ABBY Awards
Richard Carreon, managing director and CEO, to present at 19th Innovations in Healthcare Awards, Dec. 5, 2018, Long Beach Airport Marriott Hotel
MD Anderson Study Uses ImpediMed L-Dex Bioimpedance Spectroscopy to Assess Correlation with Limb Volume, Lymphatic Function in Lymphedema, Recommends L-Dex
Study concludes L-Dex correlates most closely with all measures and is the recommended metric when using BIS
ImpediMed Announces First Patient Enrolled at Scripps Memorial Hospital in 200-Patient Heart Failure Trial
ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces that the first patient has been enrolled in its 200-patient Heart Failure (HF) trial now being conducted at Scripps Memorial Hospital, San Diego, CA.
Third-Party Advocacy of ImpediMed SOZO: A New Standard of Lymphedema Care for Primary Care Physicians, Health Plans and Payers
ImpediMed Limited is pleased to announce the initial educational webinar in an series presented by Sheila Ridner Ph.D., RN, FAAN, MSN, MSHSA, BSN, principal investigator of the PREVENT trial and the Martha Rivers Ingram Professor of Nursing at Vanderbilt University School of Nursing.
ImpediMed SOZO® Abstract Presentations at Key Scientific Cardiology Meetings Demonstrate Utilization of Bioimpedance Spectroscopy for Heart Failure Patients
Utilization of Bioimpedance Spectroscopy in Lieu of Invasive Monitoring for Monitoring Fluid Overload
ImpediMed announced the launch of its new product, SOZO.